Once hailed as a potential breakthrough in Hepatitis C treatment, the drug known only as BMS-986094 soon revealed a dark side: heart and kidney damage, sometimes requiring transplants and at least once, resulting in death. The unexpected side effects were so severe that Bristol-Myers Squibb dropped development of the drug after investing almost $2 billion in acquiring it less than a year earlier, Reuters reported.
Now, people who participated in the clinical trials for this drug are coming forward, revealing the severity of the fallout. Many of these cases are currently being filed or reviewed by Thomas J. Henry.
“We have already interviewed a number of injury victims from the Hepatitis C trials,” Thomas J. Henry said. “More calls are coming in and we have current lawsuits on file and are litigating these types of matters. People have suffered life-changing debilitating injuries as a result of these clinical trials.”
Phase II of a clinical trial involving BMS-986094 (sometimes referred to as BMS094) and Daclatasvir was halted on August 1 after one person died of sudden heart failure, The New York Times reported. At least eight others were hospitalized and some news outlets have reported that 113 people were enrolled in the trial. However, Clinicaltrials.gov shows the estimated enrollment at 360. In addition, news outlets have reported that Bristol is notifying 150 patients who took part in earlier trials.
The experimental drug may be toxic to the heart and kidneys. Reported injuries include:
Trials for Hepatitis C drugs take place in various medical facilities across the country, including:
Idenix Pharmaceuticals makes two drugs very similar to BMS-986094. Due to similarities, IDX184 and IDX19368 have also been placed on clinical hold, news outlets reported. The FDA has requested more cardiac testing related to IDX184. Idenix says that no patients were exposed to IDX19368.
Information obtained from the CDC:
If you or a loved one participated in trials involving BMS-986094 or similar drugs and suffered damage, you are encouraged to contact an attorney immediately. Thomas J. Henry are available 24/7, night and day, at 1-888-956-8000 or thomasjhenrylaw.com.
Thomas J. Henry are leaders in the area of drug and product liability litigation. Our Defective Drug and Products Division have extensive knowledge and resources in order to represent our clients efficiently and aggressively. The Defective Drug and Products Division represent a multitude of people who are battling against manufacturers of medical devices and/ or defective pharmaceuticals.
If you or a loved one have been injured by or have developed serious side-effects from the use of defective medications or pharmaceuticals, contact Thomas J. Henry immediately. We are available 24/7, nights and weekends.